The latter was also a major limitation in several large clinical trials, for example, the Heart Outcomes Prevention Evaluation (HOPE) (137, 158) and the HOPE-The Ongoing Outcomes (17).
While anticipating the results of the ongoing outcome trials, several analyses with pooled data from shorter term trials have been conducted to explore the CV safety profiles of the SGLT-2 inhibitors.
20 Information on cancer histological subtypes was also collected for a subset of the cases through cancer registries or reviews of hospital medical notes as part of the ongoing outcome adjudication for major diseases.
The aims of this audit were as follows: to monitor the real-life use of DrotAA and subsequent outcomes; to undertake a rigorous, nonrandomized evaluation of the effectiveness of DrotAA, by linking the data on DrotAA to the ongoing outcome audit for all admissions to adult, general critical care units; and to compare our results with those from the PROWESS study.
The sample for the present study was drawn from participants of the ongoing Pregnancy Outcomes, Maternal and Infant Study (PrOMIS) Cohort, designed to examine maternal social and behavioral risk factors of preterm birth and other adverse pregnancy outcomes.
Removing this variability allows constant improvement through ongoing outcomes analysis and optimisation of the 'A constant' or its equivalent in IOL power calculation formulae.
This review provides an overview on the potential for SGLT-2 inhibitors to reduce CV risk beyond glucose-lowering effects and presents an overview of the similarities and differences of the currently six ongoing outcome trials from this class, currently involving more than 41,000 patients.
80, 81 Therefore, while early studies for SGLT2 inhibitors also suggest they may have beneficial effects on CVD risk (in particular, as they are associated with lowering blood pressure and inducing weight loss), 82 the ongoing CV-outcome trials are essential to provide conclusive information on clinical outcomes (see Table 2).
This phenomena is similar to treatment effects of external beam radiation therapy 26 where we appreciate that the treatment dose given is not directly proportional to the ongoing therapeutic outcome.
Nevertheless, these findings are suggestive and provide the basis for the hypothesis of a potential CV benefit of linagliptin over glimepiride, which is currently being tested in the ongoing CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
